Data

#Data #Drug development #Drug discovery #Genomics #Research study #Tuberculosis

Largest ever global TB study identifies genetic causes of drug resistance 

The Comprehensive Resistance Prediction for Tuberculosis International Consortium (CRyPTIC) research project has reportedly collected the largest ever global dataset of clinical M. tuberculosis samples from across the world consisting of 15,211 samples from 27 countries on five continents.  Using a new quantitative test for drug resistance and… Read More

#News #Trending News

#CRO #Data #Drug development

CatSci partners with Cambridge Crystallographic Data Centre 

Medicine developer CatSci has collaborated with the Cambridge Crystallographic Data Centre (CCDC). CatSci’s experimental expertise in material science combined with CCDC’s informatics tools will offer an integrated solution to customers, adding strategic value from molecule to medicine.  CCDC’s informatics-based services apply big data learnings from over one million published crystal structures to better… Read More

#News

#Clinical trials #Data #Technology

Clinical Ink acquires Digital Artefacts 

Clinical Ink, a clinical trial data and technology company, has acquired Digital Artefacts, a digital endpoint-based technology company.   “The addition of Digital Artefacts now allows us to drive situational awareness because context matters. Data derived from Digital Artefacts can now increase the richness of our partners’ study… Read More

#News

#Biology #Data #Drug discovery #Metabolomics #Precision medicine #Research

New metabolomics solution enables understanding of the microbiome 

Metabolon’s first offering from its SmartPanel portfolio aims to provide drug discovery and precision medicine researchers with a novel, dynamic process to explore biologically relevant views of metabolomic data in the context of specific metabolic pathways, biological themes, and disease associations.  “The metabolome offers a window into human… Read More

#Editor's Choice #News #Trending News

#Computer modelling #Data #Drug targets #Novel therapeutics #Therapeutics

New computer modelling could boost drug discovery 

Scientists from Queen’s University Belfast have developed a computer-aided data tool that will predict novel sites of binding for potential drugs that are more selective, leading to more effective drug targeting, increasing therapeutic efficacy and reducing side effects. The data tool or protocol will uncover a novel class of… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Data #Healthcare #Life sciences #Machine learning

Making life science data work for the digital age

The life sciences data landscape is growing in complexity and scale, with organisations generating increasingly high volumes of data. Yet, these data are still stored and searched using outdated methods. As a result, there are vast amounts of unstructured data stored… Read More

#Exclusive Content #News #Opinion

#Clinical trials #Data #Drug discovery #Life sciences

Clinical trials, the pandemic and technology 

Listen to this article on the DDW Podcast: Chris Sigley, CEO of Arkivum, says the transformation of clinical trials demands a transformed approach to trial data  The pandemic has created manifold challenges for clinical trials, but it has also proved a transformational force. The life sciences… Read More

#Exclusive Content #Trends & Analysis

#Cellular imaging #Clinical trials #Data #Imaging

Medidata hits platform milestone  

Medidata’s Rave Imaging, the company’s cloud-based, secure clinical trial imaging management platform, has now supported more than 1,000 imaging studies.   Rave Imaging processes more than 100 million images annually. The technology provides real-time visibility into imaging-related trial activities to enhance study efficiency.   Paul McCracken, VP and… Read More

#News

#Data #Drug research #Drug therapy

Early therapy gives better outcomes for ulcerative colitis patients, says data  

Galapagos presented data at the United European Gastroenterology Week (UEGW) virtual 2021 congress, which suggests patients with ulcerative colitis (UC) treated with early advanced therapy within the first 18 months post diagnosis showed less residual diarrhoea and required fewer follow-up tests than those who were treated with an advanced therapy later. Read More

#News #Trends & Analysis

#Data #Drug delivery #Lab automation #Software

Connectivity and data standards – a precondition for successful digitalisation 

  This paid-for whitepaper by The SiLA (Standardization in Lab Automation) consortium appeared in DDW Volume 22, Issue 4 – Fall 2021  R&D, manufacturing and contract research laboratories across many industries are investing in efforts to digitalise their processes and operations, with the goal of achieving… Read More

#Exclusive Content #Sponsored Content

#Biotechnology #Collaboration #Data #Technology #Webinar

Webinar reveals how to accelerate your drug discovery program 

This free-to-watch webinar, brought to you by Certara, reviews best practices for using technology to overcome challenges in order to accelerate discovery programs.  Drug discovery research requires understanding complex chemical, biological, logistical, and computational data from a variety of data sources. A key challenge for discovery scientists is efficiently… Read More

#Intelligence #News #Trends & Analysis

#Antibodies #Clinical trials #Data #Monoclonal antibodies

AstraZeneca Imfinzi combination effective with non-small cell lung cancer 

Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had… Read More

#News

#Biotechnology #Clinical trial #Data #Psychedelics

First patient receives low-dose psilocybin for rare headache disorder 

Beckley Psytech has dosed the first patient in a world-first clinical trial exploring the effects of psilocybin for treating Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA).   The outcome of the Phase Ib study, with proof-of-concept efficacy data, is expected to be available in early 2022. The clinical trial is being… Read More

#News

#Bioinformatics #Data #Life sciences

Pluto Biosciences launches collaborative life sciences platform 

Pluto Biosciences has launched a cloud-based, collaborative life sciences platform that leverages technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University. The Pluto platform simplifies secure, collaborative data sharing and bioinformatics analysis for academic, biotech, and pharmaceutical organisations.   The Pluto platform was built to… Read More

#News

#Biopharmaceuticals #Clinical trials #Data #Global data

New results in psoriasis pave way for potential best in class

UCB, a biopharmaceutical company, has presented new interim data from BE BRIGHT, an open-label extension (OLE) trial of an interleukin (IL)-17A/F inhibitor ‘bimekizumab’ for plaque psoriasis (PsO), at the 2021 American Academy of Dermatology (AAD) Summer Meeting. While the data are still preliminary, they strongly support a potential approval for… Read More

#News